Intervention Review

You have free access to this content

Cyclophosphamide versus methylprednisolone for treating neuropsychiatric involvement in systemic lupus erythematosus

  1. Virginia Fernandes Moça Trevisani1,*,
  2. Aldemar A Castro2,
  3. João Ferreira Neves Neto3,
  4. Álvaro N Atallah4

Editorial Group: Cochrane Musculoskeletal Group

Published Online: 28 FEB 2013

Assessed as up-to-date: 16 NOV 2012

DOI: 10.1002/14651858.CD002265.pub3


How to Cite

Fernandes Moça Trevisani V, Castro AA, Ferreira Neves Neto J, Atallah ÁN. Cyclophosphamide versus methylprednisolone for treating neuropsychiatric involvement in systemic lupus erythematosus. Cochrane Database of Systematic Reviews 2013, Issue 2. Art. No.: CD002265. DOI: 10.1002/14651858.CD002265.pub3.

Author Information

  1. 1

    Universidade Federal de São Paulo, Rheumatology/Internal Medicine and Therapeutics, São Paulo, São Paulo, Brazil

  2. 2

    State University of Heath Science, Department of Public Health, Maceió, Alagoas, Brazil

  3. 3

    Universidade Federal de São Paulo, Surgery, São Paulo, São Paulo, Brazil

  4. 4

    Escola Paulista de Medicina, Universidade Federal de São Paulo, Brazilian Cochrane Centre, São Paulo, São Paulo, Brazil

*Virginia Fernandes Moça Trevisani, Rheumatology/Internal Medicine and Therapeutics, Universidade Federal de São Paulo, Rua Marie Satzke 119, São Paulo, São Paulo, 04664-150, Brazil. vmoca@uol.com.br. cochrane.dmed@epm.br.

Publication History

  1. Publication Status: New search for studies and content updated (no change to conclusions)
  2. Published Online: 28 FEB 2013

SEARCH

References

References to studies included in this review

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. Additional references
Barile-Fabris 2005 {published data only}
  • Barile-Fabris L, Ariza-Andraca R, Olguin-Ortega L, Jara LJ, Fraga-Mouret A, Miranda-Limón JM, et al. Controlled clinical trial of IV cyclophosphamide versus IV methylprednisolone in severe neurological manifestations in systemic lupus erythematous. Annals of the Rheumatic Diseases 2005;64:620-5.

References to studies excluded from this review

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. Additional references
Austin 1986 {published data only}
Boumpas 1992 {published data only}
  • Boumpas DT, Austin III HA, Vaughn EM, Klippel JH, Steinberg ASD, Yarboro CH, et al. Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet 1992;340:741-5.
Cortés-Hernández 2003 {published data only}
  • Cortés-Hernández J, Ordi- Ros J, Labrador M, Segarra A, Tovar JL, Balalada E, et al. Predictors of poor renal outcome in patients with lupus nephritis treated with combined pulses of cyclophosphamide and methylprednisolone. Lupus 2003;12:287-96.
Dinant 1982 {published data only}
  • Dinant HJ, Decker JL, Klippel JH, Balow JE, Plotz PH, Steinberg AD. Alternative modes of cyclophosphamide and azathioprine therapy in lupus nephritis. Annals of Internal Medicine 1982;96(6 Pt 1):728-35.
Donatio 1977 {published data only}
  • Donatio JV, Holley KE, Ferguson RH, Istrup DM. Treatment of diffuse proliferative lupus nephritis with prednisone and combined prednisone and cyclophosphamide. New England Journal of Medicine 1978;23:1151-5.
Edwards 1987 {published data only}
  • Edwards JCW, Snaith ML, Isenberg DA. A double blind controlled trial of methylprednisolone infusions in systemic lupus erythematosus using individualised outcome assessment. Annals of the Rheumatic Diseases 1987;46:773-6.
Euler 1991 {published data only}
  • Euler HH, Schroeder JO, Zeuner RA, Teske E. A randomised trial of plasmapheresis and subsequent pulse cyclophosphamide in severe lupus: design of the LPSG trial. International Journal of Artificial Organs 1991;14(10):639-46.
Fries 1973 {published data only}
Gourley 1996 {published data only}
  • Gourley MF, Austin HA 3rd, Scott D, Yarboro CH, Vaughan EM, Muir J, et al. Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. Annals of Internal Medicine 1996;125(7):549-57.
Harisdangkul 1989 {published data only}
  • Harisdangkul V, Rockhold L, Myers A. Lupus nephritis: efficacy of monthly pulse therapy with intravenous methylprednisolone. Southern Medical Journal 1989;82(3):321-7.
Kopelman 2003 {published data only}
Lavalle-Graef 2004 {published data only}
  • Lavalle-Graef A,  Villegas-Acosta L,  Lavalle C. Trends of anticardiolipin antibodies after low-dose methylprednisolone and cyclophosphamide treatment of systemic lupus erythematosus. Archives of Medical Research 2004;35:421-7.
Lehman 2004 {published data only}
Levey 1992 {published data only}
  • Levey AS, Lan S-P, Corwin HL, Kasinath BS, Lachin J, Neilson EG, et al. Progression and remission of renal disease in the lupus nephritis collaborative study. Annals of Internal Medicine 1992;116(2):114-23.
Liebling 1982 {published data only}
  • Liebling MR, McLaughlin K, Boonsue S, Kasdin J, Barnett EV. Monthly pulses of methylprednisolone in SLE nephritis. Journal of Rheumatology 1982;9:543-8.
Mackworth-Young 1988 {published data only}
  • Mackworth-Young CG, David J, Morgan SH. A double blind, placebo controlled trial of intravenous methylprednisolone in systemic lupus erythematosus. Annals of the Rheumatic Diseases 1988;47:496-502.
Mok 2003 {published data only}
Neuwelt 1995 {published data only}
  • Neuwelt CM, Lacks S, Kaye BR, Ellamn JB, Borestein DG. Role of intravenous cyclophosphamide in the treatment of severe neuropsychiatric systemic lupus erythematosus. American Journal of Medicine 1995;98:32-41.
Ramos 1996 {published data only}
  • Ramos PC, Mendez PRJ, Ames MA, Khamashta, Hughes GRV. Pulse cyclophosphamide in the treatment of neuropsychiatric systemic lupus erythematosus. Clinical and Experimental Rheumatology 1996;14:295-9.
Sesso 1994 {published data only}
Steinberg 1971 {published data only}
  • Steinberg AD, Kaltreider HB, Staples PJ, Goetzl EJ, Talal N, Decker JL. Cyclophosphamide in lupus nephritis: a controlled trial. Annals of Internal Medicine 1971;75:165-71.
Steinberg 1991 {published data only}
  • Steinberg AD, Steinberg SC. Long-term preservation of renal function in patients with lupus nephritis receiving treatment that includes cyclophosphamide versus those treated with prednisone only. Arthritis & Rheumatism 1991;34(8):945-9.
Stojanovich 2003 {published data only}
Stratta 1992 {published data only}
  • Stratta P, Canavese C, Dogliani M, Thea A, Ferrero S, Tognarelli G, et al. Intravenous cyclophosphamide pulse therapy in the treatment of systemic lupus erythematosus. Contributions to Nephrology 1992;99:126-8.
Yee 2003 {published data only}
  • Yee CS,  Gordon C,  Dostal C,  Petera P,  Dadoniene J,  Griffiths B,  et al. EULAR randomised controlled trial of pulse cyclophosphamide and methylprednisolone versus continuous cyclophosphamide and prednisolone followed by azathioprine and prednisolone in lupus nephritis. Annals of the Rheumatic Diseases 2003;63:525-9.

Additional references

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. Additional references
Aranow 2008
  • Aranow C, Ginzler EM. Treatment of non-renal lupus. Rheumatology. Vol. 2, Mosby, 2008:1309-18.
Bertsias 2010
  • Bertsias GK,  Ioannidis JP,  Aringer M,  Bollen E,  Bombardieri S,  Bruce IN, et al. EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee affairs. Annals of the Rheumatic Diseases 2010;69:2074-82.
Bonfa 1987
Boumpas 1995
  • Boumpas DT, Austin HA, Fessler BJ, James E, Ballow JE, Klippel JH, et al. Systemic lupus erythematosus; emerging concepts. Annals of Internal Medicine 1995;122:940-50.
Denburg 1994
Denburg 1995
  • Denburg JA, Denburg SD, Carbotte RM, Sakic B, Szechtman H. Nervous system lupus: pathogenesis and rationale for therapy. Scandinavian Journal of Rheumatology 1995;12:263-73.
Eyanson 1980
Felson 1984
Gladman 1994
  • Gladman DD, Urowitz MB. Clinical features of systemic lupus erythematosus. In: Klippel JH, Dieppe PA editor(s). Rheumatology. Baltimore: Mosby, 1994:(6) 2.1-2.20.
Gono 2011
  • Gono T,  Kawaguchi Y,  Kaneko H,  Nishimura K,  Hanaoka M,  Kataoka S, et al. et al. Anti-NR2A antibody as a predictor for neuropsychiatric systemic lupus erythematosus. Rheumatology 2011;50(9):1578-85.
Higgins 2011
  • Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
Schünemann 2011
  • Schünemann HJ, Oxman AD, Higgins JPT, Vist GE, Glasziou P, Guyatt GH. Chapter 11: Presenting results and ‘Summary of findings' tables. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1. 0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org. Chapter 11: Presenting results and ‘Summary of findings’ tables.
Sibley 1992
  • Sibley JT, Olszynski PW, Decoteau WE, Sundaram MB. The incidence and prognosis of central nervous system disease in systemic lupus erythematosus is independent of active disease. Journal of Rheumatology 1992;19:47-52.
Tan 1982
Urowitz 1980
  • Urowitz M, Gladman DD, Abel T. Neuropsychiatric lupus. Journal of Rheumatology 1980;7:326-33.
Wolkowitz 1990